John E. Levine, Stephan Grupp, Michael A. Pulsipher, Andrew C. Dietz, Susana Rives, G. Douglas Myers, Keith J. August, Michael R. Verneris, Jochen Büchner, Theodore W. Laetsch, Henrique Bittencourt, Andre Baruchel, Michael W. Boyer, Barbara De Moerloose, Muna Qayed, Stella M. Davies, Christine L. Phillips, Timothy A. Driscoll, Peter Bader, Krysta Schlis, Patricia A Wood, Rajen Mody, Lan Yi, Mimi Leung, Lamis K. Eldjerou, Carl H. June, Shannon L Maude
- Background: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096 (ENSIGN)), leading to commercialization of tisagenlecleucel for the treatment of patients up to age 25 years with B-ALL that is refractory or in second or greater relapse.
Methods: A pooled analysis of 137 patients from these trials (ELIANA: n=79; ENSIGN: n=58) was performed to provide a comprehensive safety profile for tisagenlecleucel.
Results: Grade 3/4 tisagenlecleucel-related adverse events (AEs) were reported in 77% of patients. Specific AEs of interest that occurred ≤8 weeks postinfusion included cytokine-release syndrome (CRS; 79% (grade 4: 22%)), infections (42%; grade 3/4: 19%), prolonged (not resolved by day 28) cytopenias (40%; grade 3/4: 34%), neurologic events (36%; grade 3: 10%; no grade 4 events), and tumor lysis syndrome (4%; all grade 3). Treatment for CRS included tocilizumab (40%) and corticosteroids (23%). The frequency of neurologic events increased with CRS severity (p<0.001). Median time to resolution of grade 3/4 cytopenias to grade ≤2 was 2.0 (95% CI 1.87 to 2.23) months for neutropenia, 2.4 (95% CI 1.97 to 3.68) months for lymphopenia, 2.0 (95% CI 1.87 to 2.27) months for leukopenia, 1.9 (95% CI 1.74 to 2.10) months for thrombocytopenia, and 1.0 (95% CI 0.95 to 1.87) month for anemia. All patients who achieved complete remission (CR)/CR with incomplete hematologic recovery experienced B cell aplasia; however, as nearly all responders also received immunoglobulin replacement, few grade 3/4 infections occurred >1 year postinfusion.
Conclusions: This pooled analysis provides a detailed safety profile for tisagenlecleucel during the course of clinical trials, and AE management guidance, with a longer follow-up duration compared with previous reports.
MetadatenAuthor: | John E. LevineORCiDGND, Stephan GruppORCiD, Michael A. PulsipherORCiD, Andrew C. Dietz, Susana RivesORCiD, G. Douglas Myers, Keith J. AugustORCiD, Michael R. VernerisORCiD, Jochen BüchnerORCiDGND, Theodore W. LaetschORCiD, Henrique Bittencourt, Andre BaruchelORCiD, Michael W. Boyer, Barbara De MoerlooseORCiD, Muna Qayed, Stella M. Davies, Christine L. Phillips, Timothy A. Driscoll, Peter BaderORCiDGND, Krysta Schlis, Patricia A Wood, Rajen Mody, Lan Yi, Mimi Leung, Lamis K. Eldjerou, Carl H. JuneORCiDGND, Shannon L MaudeORCiD |
---|
URN: | urn:nbn:de:hebis:30:3-629858 |
---|
DOI: | https://doi.org/10.1136/jitc-2020-002287 |
---|
ISSN: | 2051-1426 |
---|
Parent Title (English): | Journal for ImmunoTherapy of Cancer |
---|
Publisher: | BioMed Central |
---|
Place of publication: | London |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2021/08/05 |
---|
Date of first Publication: | 2021/08/05 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2024/03/11 |
---|
Volume: | 9.2021 |
---|
Issue: | 8, art. e002287 |
---|
Article Number: | e002287 |
---|
Page Number: | 12 |
---|
First Page: | 1 |
---|
Last Page: | 12 |
---|
Note: | Data are available on reasonable request. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com. |
---|
Note: | PAW is deceased. |
---|
Note: | These studies and writing assistance were funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Representatives of the sponsor participated in study design, collection, data interpretation, and development/submission of the manuscript. |
---|
HeBIS-PPN: | 521819636 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - CC BY-NC - Namensnennung - Nicht kommerziell 4.0 International |
---|